NeuroNOS Receives FDA's Orphan Drug Designation For BA-102 In Treating Rare Phelan-McDermid Syndrome
22/4 03:06
(RTTNews) - NeuroNOS, a subsidiary of Beyond Air (XAIR), announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead investigational therapy, BA-102, for the treatment of Phelan-McDermid Syndrome (PMS), a syndrome associated with Autism Sp...